Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial

INTRODUCTION: The efficacy of natalizumab was evaluated in Japanese patients with relapsing-remitting multiple sclerosis (RRMS) in a 24-week, phase 2 bridging study. An open-label, 2-year extension study from this trial was conducted to assess the safety and efficacy of natalizumab treatment in Japa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurol Ther
Main Authors: Saida, Takahiko, Kira, Jun-Ichi, Kishida, Shuji, Yamamura, Takashi, Ohtsuka, Nobuhisa, Ling, Yan, Torii, Shinichi, Lucas, Nisha, Kuesters, Geoffrey, Steiner, Deb, Tibung, J. T.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5447552/
https://ncbi.nlm.nih.gov/pubmed/27921221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-016-0059-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados